20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety of apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in patients with advanced gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed.

          Related collections

          Author and article information

          Journal
          J. Clin. Oncol.
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          1527-7755
          0732-183X
          May 1 2016
          : 34
          : 13
          Affiliations
          [1 ] Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun;
          Article
          JCO.2015.63.5995
          10.1200/JCO.2015.63.5995
          26884585
          3466fc53-7236-4385-9ee2-1e2755060f00
          © 2016 by American Society of Clinical Oncology.
          History

          Comments

          Comment on this article